Mergers & Acquisitions - Mergers & Acquisitions, Research

Filter

Popular Filters

1 to 25 of 67 results

Biotie passes up on option to acquire Neurelis

Biotie passes up on option to acquire Neurelis

14-07-2014

Finland-based biotech firm Biotie Therapies said on Friday that it has decided not to exercise its exclusive…

Acute repetitive seizuresBiotechnologyBiotie TherapiesDiazepamFinlandHepatologyMergers & AcquisitionsNeurelisNeurologicalNRL-1Pediatric and adult epilepsyPharmaceuticalResearchtozadenant

Roche invests in Stratos Genomics for “Sequencing by Expansion”

Roche invests in Stratos Genomics for “Sequencing by Expansion”

26-06-2014

Swiss pharma major Roche has made a strategic investment in USA-based Stratos Genomics and entered into…

BiotechnologyMergers & AcquisitionsResearchRocheStratos Genomics

Roche partners in new company for MS research

Roche partners in new company for MS research

23-06-2014

Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Ohr Pharma and Cold Spring Harbor Lab set up JV to develop trodusquemine

03-03-2014

US biotech firm Ohr Pharmaceutical and not-for-profit cancer research center Cold Spring Harbor Laboratory…

BiotechnologyDepYmedMergers & AcquisitionsOhr PharmaceuticalResearchtrodusquemine

Perrigo transfers ELND005 assets; buys OTC products

01-03-2014

Drugmaker Perrigo has entered into a series of agreements with existing collaboration partner, Transition…

ELND005Mergers & AcquisitionsNeurologicalPerrigoPharmaceuticalResearchTransition Therapeutics

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

Moderna spins-out Onkaido Therapeutics to focus on mRNA therapeutics in oncology

15-01-2014

Flush with cash as a result of its mega-million dollar deal with Alexion on the development of drugs…

Mergers & AcquisitionsModerna TherapeuticsOncologyOnkaido TherapeuticsPharmaceuticalResearch

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

NeXeption forms new company, Alexar Therapeutics, to develop novel LXR agonist portfolio

03-01-2014

US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to…

A-110Alexar TherapeuticsDermatologicalsFinancialMergers & AcquisitionsNeXeptionPharmaceuticalResearch

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Merck KGaA eighth EPP spin-off to focus on infertility treatment

Merck KGaA eighth EPP spin-off to focus on infertility treatment

02-12-2013

USA-based EMD Serono, one of German drug and chemical group Merck KGaA’s biotechnology subsidiaries,…

BiotechnologyEMD SeronoMerck KGaAMerck SeronoMergers & AcquisitionsReproductiveResearchTocopheRx

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

09-10-2013

PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Briefs: Depomed drops Sefelsa after CRL: Sun Pharma stalking Meda?

03-06-2013

US specialty drugmaker Depomed (Nasdaq: DEPO) says that Food and Drug Administration issued a complete…

DepomedMedaMergers & AcquisitionsMetabolicsNorth AmericaPharmaceuticalRegulationResearchSefelsaSun Pharmaceutical Industries

Biotech industry has "implementation gap" around demonstrating the value of products under development

07-05-2013

Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Ligand acquires financial rights to over 15 development programs from Selexis

01-05-2013

US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a portfolio of potential future milestone…

BiotechnologyLigand PharmaceuticalsMergers & AcquisitionsResearchSelexis

Briefs: Royalty sweetens offer for Elan; AstraZeneca biomarker deal

16-04-2013

US private equity company Royalty Pharma today (April 15) issued a firm improved takeover offer for Ireland-based…

AstraZenecaElanLicensingMergers & AcquisitionsOncologyOxford Cancer BiomarkersPharmaceuticalResearchRoyalty Pharma

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

1 to 25 of 67 results

Back to top